Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 2248

Reviews
Table of Contents - Year : 2018 | Month : August | Volume : 12 | Issue : 8 | Page : XE01 - XE06

A Review on Newer Tyrosine Kinase Inhibitors and their Uses XE01-XE06

Nithu M Kumar, Meenu Mathew, KN Anila, S Priyanka

Correspondence
Ms. KN Anila,
Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi-682041, Kerala, India.
E-mail: anilakn@aims.amrita.edu

Tyrosine Kinase Inhibitors (TKI) can reversibly or irreversibly block the signaling pathway occurring in the extracellular part of the receptor by inhibiting Tyrosine Kinase (TK) phosphorylation. This review included the drugs that were newly marketed or drugs with newer approved uses after 2015, such as Gefitinib, Osimertinib, Crizotinib, Alectinib, Ibrutinib, Cabozantinib. Brigatinib and Lorlatinib are investigational drugs that have not been approved and have shown promising results in trials for the treatment of Anaplastic Lymphoma Kinase (ALK) positive metastatic Non Small Cell Lung Carcinoma (NSCLC). Gefitinib, Osimertinib, Crizotinib, Alectinib were approved for treating NSCLC. Cabozantinib and Lenvatinib were approved for treating renal cell carcinoma and thyroid carcinoma. Ibrutinib was approved for treatment of Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Waldenström macroglobulinemia, previously treated Mantle cell lymphoma and relapsed or refractory Marginal zone lymphoma. TKI have promising efficacy in treating a wide range of oncologic diseases. Hand-foot-skin reaction are the most common side effect of drugs in this category, however, TKI are found to have relatively fewer side effects compared to other anti cancer drugs.